These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 26865419

  • 1. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H, Kitadai Y, Shinagawa K, Yuge R, Higashi Y, Tanaka S, Yasui W, Chayama K.
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [Abstract] [Full Text] [Related]

  • 2. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
    Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M, Ohnishi M, Ohara E, Higashi Y, Tanaka S, Yasui W, Chayama K.
    Int J Cancer; 2013 Feb 15; 132(4):813-23. PubMed ID: 22821812
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
    Wang ZH, Li Q, Ruan SQ, Xiao Q, Liu Y, Hu YT, Hu LF, Chen HY, Zheng S, Zhang SZ, Ding KF.
    J Zhejiang Univ Sci B; 2014 Aug 15; 15(8):701-12. PubMed ID: 25091988
    [Abstract] [Full Text] [Related]

  • 4. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
    Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D.
    Int J Cancer; 2011 Jul 01; 129(1):245-55. PubMed ID: 21170960
    [Abstract] [Full Text] [Related]

  • 5. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
    Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ.
    Am J Pathol; 2006 Dec 01; 169(6):2054-65. PubMed ID: 17148668
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mesenchymal stem cells enhance growth and metastasis of colon cancer.
    Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W, Chayama K.
    Int J Cancer; 2010 Nov 15; 127(10):2323-33. PubMed ID: 20473928
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ, Keisler MD, Walko CM.
    Ann Pharmacother; 2013 Dec 15; 47(12):1685-96. PubMed ID: 24259629
    [Abstract] [Full Text] [Related]

  • 10. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
    Mehta M, Griffith J, Panneerselvam J, Babu A, Mani J, Herman T, Ramesh R, Munshi A.
    Int J Radiat Biol; 2021 Dec 15; 97(8):1109-1120. PubMed ID: 32052681
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regorafenib.
    Ettrich TJ, Seufferlein T.
    Recent Results Cancer Res; 2014 Dec 15; 201():185-96. PubMed ID: 24756792
    [Abstract] [Full Text] [Related]

  • 13. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC, Tsai JJ, Weng YS, Hsu FT.
    Biomed Pharmacother; 2020 Aug 15; 128():110319. PubMed ID: 32502841
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
    Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS.
    Ann Hematol; 2018 May 15; 97(5):839-849. PubMed ID: 29359239
    [Abstract] [Full Text] [Related]

  • 17. Regorafenib for cancer.
    Strumberg D, Schultheis B.
    Expert Opin Investig Drugs; 2012 Jun 15; 21(6):879-89. PubMed ID: 22577890
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H, Ong R, Zopf D.
    J Exp Clin Cancer Res; 2015 Oct 29; 34():132. PubMed ID: 26514182
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM, Zopf D.
    Int J Cancer; 2014 Sep 15; 135(6):1487-96. PubMed ID: 24347491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.